ABSTRACT
Background: ALG-000184 is a prodrug of ALG-001075, a novel, potent, pan-genotypic Class II CAM. CAMs are thought to have two mechanisms of action (MoA). The primary MoA affects pgRNA encapsidation resulting in inhibition of HBV DNA/RNA replication, as confirmed in CHB subjects receiving ALG-000184. The secondary MoA, which occurs at higher concentrations, regulates the establishment and replenishment of cccDNA, resulting in lowering of HBsAg, an effect that has not been reported to date with ALG- 000184. Method(s): ALG-000184-201 is a multi-part, multicenter, doubleblind, randomized, placebo-controlled study. In healthy volunteers (HVs), single doses up to 500 mg and multiple doses up to 250 mg were well tolerated with linear PK (Gane E., HBV TAG and APASL 2021). In treatment naive (TN) subjects with CHB, daily oral doses of 10-100 mg ALG-000184 for 28 days were well tolerated with linear PK and were associated with profound reductions of DNA/RNA regardless of HBeAg status or dose (Yuen MF, EASL 2022). Plasma exposures required to engage the secondary MoA are expected to be achieved at the 300 mg dose level. Data from a 300 mg cohort treated for 28 days are described here. Data from another ongoing cohort treated with 300 mg for 12 weeks will be presented at the conference. Result(s): Ten subjects were randomized to 300 mg ALG-000184 for 28 days and two to placebo. Two subjects randomized to ALG- 000184 were replaced due to missing data due to Covid-19 lockdown. Subjects were Asian, HBeAg positive, and genotype B or C. Mean baseline HBV DNA and RNA levels were 8.4 log10 IU/mL and 7.3 log10 copies/mL, respectively. One subject experienced a serious adverse event (AE) of pneumothorax>8 weeks after last dose which was considered unlikely related to study drug. No subjects prematurely discontinued study drug. All treatment emergent AEs were Grade <= 2 except for 4 Grade >= 3 alanine aminotransferase (ALT) elevations, which an independent ALT Flare Committee assessed as not related to study drug toxicity. PK was similar to HBeAg negative and HV cohorts following body weight adjustment. Subjects dosed with 300 mg ALG-000184 experienced mean declines of 4.0 log10 IU/mL and 2.6 log10 copies/mL in HBV DNA and RNA levels, respectively, at Day 28. Three of 7 evaluable subjects who received ALG-000184 had HBsAg declines>0.2 log10 IU/mL (0.23-0.78 log10 IU/mL). One subject receiving ALG-000184 had unquantifiable HBsAg throughout the study. Additionally, one HBeAg positive subject in a prior 100 mg cohort had plasma exposures equivalent to the 300 mg dose level and experienced a 0.5 log10 IU/mL HBsAg decline. Conclusion(s): In TN HBeAg positive CHB subjects, 300 mg ALG- 000184 for 28 days was well tolerated, exhibited predictable PK and resulted in rapid and substantial declines in HBV DNA and RNA. Notably, 3 of 7 evaluable subjects from this cohort experienced HBsAg declines of up to 0.78 log10 IU/mL. These data suggest that ALG-000184 can engage the secondary MoA of CAM II. Cohorts evaluating 300 mg over longer durations are planned or ongoing.
ABSTRACT
Background: During the initial rollout of COVID-19 vaccination in Singapore, the Ministry of Health (MOH) issued recommendations that patients with a history of any previous vaccine allergy be referred to an allergist for further review on suitability to proceed with mRNA-based COVID-19 vaccines. We review the evaluation of these patients with suspected vaccine allergies prior to receiving mRNA-based COVID-19 vaccines. Method(s): Between 8 April and 22 September 2021, 304 patients were evaluated prior to receiving the COVID-19 vaccinations. Of these, 63 (20.7%) patients with suspected immediate hypersensitivity reactions to non-COVID polysorbate-containing vaccines proceeded to have skin prick test (SPT) and Intradermal test (IDT) to polyethylene glycol (PEG)-3350, polysorbate 80 and polysorbate 20 containing products. Another 62 (20.4%) who reported delayed hypersensitivity reactions to polysorbate-containing vaccines proceeded to have direct inoculation (DI) of the Pfizer BNT162b2 vaccine under the supervision of an allergist. The remaining 242 (76.6%) finally assessed not allergic polysorbate-or tolerated previous non-polysorbate- containing vaccines were recommended to proceed with COVID-19 vaccinations at the community vaccination sites. 99 patients in the SPT/IDT and DI group completed a questionnaire-based survey to report any post vaccination reactions. (Figure 1) Results: Of 63 patients who underwent SPT/IDT, 2 (3.2%) with equivocal IDT tolerated both doses of the BNT162b2 vaccine without major allergic reactions. 61 (6.8%) patients with negative SPT/IDT and 62 (100%) in the DI group completed both doses of BNT162b2 vaccination without major reactions. Among those who completed the questionnaire survey, 13 (13%) reported reactions including non-specific rashes and mild urticaria/angioedema post first dose vaccine. All subsequently completed the second dose of the BNT162b2 vaccine following allergist review;with 8 (61.5%) reporting similar mild skin reactions. Conclusion(s): Majority of those with suspected reactions to polysorbate containing vaccines are able to tolerate the BNT162n2 vaccine which contains PEG-2000. Skin tests prior to mRNA COVID-19 vaccination is unnecessary. Those who report mild potentially allergic reactions after the first dose are able to tolerate the second dose of the BNT162b2 vaccine.
ABSTRACT
There is an ever-urgent need for accessing real-time crowdedness and airflow information for indoor study spaces in universities, for example, to control COVID-19 transmission risk. Even before the pandemic, many students spent valuable time finding suitable study areas with proper lighting, low noise, and ample seating. This paper presents a pilot system, CampusX, which aims to provide students with useful real-time information about study spaces on campus. Our system collects and analyzes environmental data before presenting them to students as useful information. This helps them to select the most suitable study spaces. The main components of this system include a sensor platform, data collection and processing pipelines, networking, and an interactive web-application. © 2023 IEEE.
ABSTRACT
The ravages of the COVID-19 and the continuous mutation of the COVID-19 make this war without gunpowder smoke unstoppable. With the continuous epidemic prevention and control, the resident closure and isolation by community is an effective way to block the large-scale development of the COVID-19. However, the shortage of daily necessities for residents during the lockdown period requires timely arrangements and deployment by local departments to ensure the basic living of the residents under lockdown. A necessary distribution and circulation system in the epidemic prevention and control community was designed and developed in this paper. The proposed necessity distribution and circulation system is mainly to help the government distribute supplies to residents and the circulation of necessities between residents more efficiently. The design process of the system includes the software development process of demand analysis, overall design, detailed design and programming;it was adopted CS three-tier architecture software development mode and the software development technology of .Net + SQLSERVER. The main business modules of the system are including necessity circulation between residents, government supply management, and volunteer necessity delivery business. The system can also be applied to the necessity circulation subsystem of the community healthy life service platform for the daily life of residents. © 2022 ACM.
ABSTRACT
This paper presents our solution for the 2nd COVID-19 Competition, occurring in the framework of the AIMIA Workshop at the European Conference on Computer Vision (ECCV 2022). In our approach, we employ the winning solution last year which uses a strong 3D Contrastive Mixup Classification network (CMC_v1) as the baseline method, composed of contrastive representation learning and mixup classification. In this paper, we propose CMC_v2 by introducing natural video priors to COVID-19 diagnosis. Specifically, we adapt a pre-trained (on video dataset) video transformer backbone to COVID-19 detection. Moreover, advanced training strategies, including hybrid mixup and cutmix, slice-level augmentation, and small resolution training are also utilized to boost the robustness and the generalization ability of the model. Among 14 participating teams, CMC_v2 ranked 1st in the 2nd COVID-19 Competition with an average Macro F1 Score of 89.11%. © 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG.
ABSTRACT
This paper presents our solution for the 2nd COVID-19 Severity Detection Competition. This task aims to distinguish the Mild, Moderate, Severe, and Critical grades in COVID-19 chest CT images. In our approach, we devise a novel infection-aware 3D Contrastive Mixup Classification network for severity grading. Specifically, we train two segmentation networks to first extract the lung region and then the inner lesion region. The lesion segmentation mask serves as complementary information for the original CT slices. To relieve the issue of imbalanced data distribution, we further improve the advanced Contrastive Mixup Classification network by weighted cross-entropy loss. On the COVID-19 severity detection leaderboard, our approach won the first place with a Macro F1 Score of 51.76%. It significantly outperforms the baseline method by over 11.46%. © 2023, The Author(s), under exclusive license to Springer Nature Switzerland AG.
ABSTRACT
The separation of highly pure single-chirality single-walled carbon nanotubes (SWCNTs) is challenging and also in demand due to their intrinsic physical, optical, and electronic properties. The use of single-chirality and their performance characteristics makes them a selective candidate for multifunctional applications and opens a new front in nanotube development. It has previously been reported that SWCNTs can be separated in various ways by employing direct control and post-synthesis approaches. Herein, we review the separation of single-chiralities of SWCNTs on account of simplicity and time/cost effectiveness by using gel chromatography. The most recent progress in the controlled synthesis of SWCNTs is comprehensively reviewed in terms of selective-diameter, single-chirality, and specific geometric shape. The method to achieve the single-chirality of SWCNTs is also highlighted. Besides addressing COVID-19 characteristics, epidemiology, and pathology, we also review the most recent developments in nano-biosensors for the rapid and early detection of COVID-19. Furthermore, the photothermal/bioimaging response of single-chirality is reviewed in order to enhance the cytotoxicity of drugs against cancer cells over simple carbon nanotubes (CNTs). The single-chirality allows for precise imaging (due to efficient absorption and emission) of tumors/blood vessels up to ~10-fold higher by injecting a low dose. We hope this review stimulates further study on single-chirality controlled SWCNTs for practical applications. Copyright © 2023 The Royal Society of Chemistry.
ABSTRACT
The outbreak of COVID-19 has significantly affected the development of enterprises. In the post-pandemic era, blockchain technology has become one of the important technologies to help enterprises quickly gain market competitiveness. The heavy investment required of supply chain stakeholders to employ blockchain technology has hindered its adoption and application. To tackle this issue, this study aims to facilitate the adoption of blockchain technology in a supply chain consisting of a core enterprise and a small/medium-sized enterprise through an effective supply chain contract. We analyze the performance of a cost-sharing (CS) contract and a revenue-sharing (RS) contract and propose a new hybrid CS-RS contract for better performance. We conduct comparative analyses of the three contracts and find that the hybrid CS-RS contract can more effectively incentivize both parties to reach the highest level of blockchain technology adoption and achieve supply chain coordination.
ABSTRACT
Introduction: COVID19 infection has been linked to various glomerulonephropathies (GN) including collapsing focal segmental glomerulosclerosis, pauciimmune crescentic glomerulonephritis, and possibly minimal change disease and IgA nephropathy. Case Description: A 57-year-old obese man with hypertension, hyperlipidemia, prediabetes, chronic obstructive pulmonary disease, illicit drug use, status post Pfizer COVID vaccine (1st dose 4m prior, 2nd dose 3w later), and COVID19 infection 7w prior, presented with an acute onset purpuric rash that began from bilateral hands and feet and progressed to arms and legs. Patient denied joint pain or abdominal discomfort. Initial studies: Serum creatinine (Cr) 4.17 mg/dL (2.37 mg/dL 2w prior, baseline 0.93 mg/dL 4m prior). Urinalysis: > 50 red blood cells/high power field;Urine protein/Cr 4g/g, albumin/Cr >3g/g;Negative: HIV, ANCA, ANA, antiGBM, complements. Chest CT: Bilateral multifocal consolidative opacities concerning for aspiration, multifocal bacterial or viral pneumonia, or atypical presentation of COVID19 pneumonia. Skin biopsy: Leukocytoclastic vasculitis;No immunoreactants detected. Patient suffered from rapid respiratory deterioration, multiple hypotensive episodes, and acute kidney injury requiring mechanical ventilation and dialysis support. Kidney biopsy: IgA dominant immune complex mediated glomerulonephritis with focal/remote fibrous crescents;acute tubular injury. Treatment: Intravenous methylprednisolone 250 mg x 3d, followed by oral prednisone course. Patient recovered adequate function after 6w and was able to discontinue dialysis. Discussion(s): COVID19 infection-related inflammatory response may precipitate GN in susceptible individuals. Crescentic IgAN is known to be associated with acute inflammatory conditions involving lungs, gastrointestinal tract, and skin. The timeline for the development of cIgAN herein raises suspicion for COVID19 infection/pneumonia as the inciting event. (Figure Presented).
ABSTRACT
Introduction: Kidney transplant (KTx) generally requires mIST to prevent rejection and graft loss. A mother-to-son kidney recipient presents with preserved kidney function despite being off mIST for 26 years. Case Description: A 44-year-old man with diabetes mellitus, unknown congenital kidney disease requiring peritoneal dialysis for 3y and KTx from his mother at age 13, and status post COVID19 infection 2m prior, presents with diabetic ketoacidosis due to insulin nonadherence. Patient received unknown mIST until age 18 when he self-discontinued therapy. Initial studies: Serum: glucose1064 mg/dL, pH 7.28, +ketones, creatinine (Cr) 2.4 mg/dL (baseline Cr 1.1);Urinalysis 4-10 white blood cells/high power field, few bacteria;Urine protein/Cr 0.4 g/g, albumin/Cr 0.1 g/g Patient received insulin and fluid with Cr improved to 1.1 mg/dL. Fig 1 shows Cr timeline. Kidney biopsy was performed prior to discharge to determine the need for mIST reinitiation. While awaiting for pathology report as outpatient, Cr increased to 1.82 mg/dL. Pathology Fig 2: Chronic active T-cell-mediated tubulointerstitial rejection, active vascular rejection, and chronic active antibody-mediated rejection. Patient was readmitted for intravenous immunoglobulin & antithymocyte globulin with appropriate Cr improvement and discharged on prednisone, mycophenolate, & tacrolimus. Donor HLA-typing was not available for donor specificic antibody testing. Discussion(s): The case demonstrates 1) Subclinical rejection may occur in the setting of prolonged IST discontinuation and 2) Cr is insensitive in detecting rejection and raises the possibility of COVID19-induced exacerbation of ongoing low-level rejection. (Figure Presented).
ABSTRACT
COVID-19 mainly causes the collapse of the pulmonary system thereby causing a dearth of oxygen in the human body. Patients infected with this viral disease have been reported to experience various signs and symptoms associated with brain dysfunction, from the feeling of vagueness to loss of smell and taste to severe strokes. These neurological problems have been reported by younger COVID-19 infected patients mainly in their thirties and forties. Various researchers from around the globe have discerned numerous other brain dysfunctions, such as headache, dizziness, numbness, major depressive disorder, anosmia, encephalitis, febrile seizures, and Guillain-Barre syndrome. The involvement of the CNS by this viral infection has been predicted to be for a longer period of time, even if the patient recovers from COVID-19. The neuronal cell damage caused by COVID-19 is a potent factor responsible for cognitive, behavioral, and psychological problems among its sufferers. The hypoxic conditions can also trigger the formation of beta-amyloid plaques and tau-tangles and thus the virus can even induce Alzheimer's in patients in the near future. The virus affects the brain directly, thereby causing encephalitis. This pandemic has also been shown to have a negative psychological toll on people. This research aims to highlight the brain dysfunction associated with the ACE2 receptor that is known to be a crucial player in the COVID-19 pandemic using genetic networking approaches. Furthermore, we have identified herbal drug candidates that bind to the ACE2 receptor in order to identify potential treatments for the neurological manifestations of COVID-19.
ABSTRACT
Due to the increase of social media usage, the online sharing of content has been extremely increased. As a result, the spread of misinformation on social media platforms has also increased. To address this issue, we proposed an approach that predicts the news is fake or real. In our approach, we select the top k ranked features through a filter base algorithm and feed them to the classifier. The main objective of this research is to provide two things. First, to provide an approach, which compares the benchmark performance results of the evolutionary detection approach on the Koirala dataset. The second is to build, publicly available dataset through web scraping for the classification of COVID-19 fake news articles. Our method significantly uplifts the F1-score with 14.88 percent for the same number of features selected 605 for the already existing approach. Also, stated the number of features 5000 on which the approach showed the best results with a margin of F1-score of 20.4 percent, respectively. Similarly, on the self-build dataset, this approach also outshines and achieved 99.66 percent of F1-score, respectively. Our experimental results show that our robust approach by comparing with other classifiers and existing approach, Max-Min Ratio (MMR) along with support vector machine (SVM) outperformed on both of these datasets. Hence, feature selection plays a vital role in the performance of the model rather than deeply tuning and training the classifier.
ABSTRACT
Background:Symptoms after SARS-CoV-2 primary vaccination among patients with inflammatory bowel disease (IBD) are generally similar to the general population,although symptoms after the second dose are more frequent and severe than after the first dose.Postvaccination symptoms after a 3rd mRNA vaccine dose in the predominantly immune-compromised IBD population is unknown.Methods:Adults with IBD participating in the prospective Coronavirus Risk Associations and Longitudinal Evaluation in IBD (CORALE-IBD) vaccine registry who received a 3rd mRNA vaccine dose were asked to complete a detailed symptom survey 1 week after vaccination.Symptoms were assessed across 11 organ systems,and graded as mild,moderate,or severe,or requiring hospitalization.“Severe+” referred to those with severe symptoms or who required hospitalization.We stratified by age (<or> 50 years) given prior distinct symptom profiles after dose 2 (D2).We also evaluated whether severe+ symptoms after D2 predicted severe+ symptoms after dose 3 (D3).Results:We included 524 participants (70% female, mean age 45 years) who received a 3rd mRNA vaccine through October 11, 2021.Most had Crohn's disease (71%), and 89% were on biologic therapies.Most (58%) had received primary vaccination with BNT562b2,and only 3.5% reported prior COVID infection at the time of initial vaccination.Overall, 97% of subjects received a 3rd dose with the same mRNA vaccine as in their initial series with the remainder receiving the other mRNA vaccine type.No participants received a 3rd dose with the Ad26.CoV.2 (J&J) vaccine. Overall, 41% reported symptoms after a 3rd dose,with symptoms generally more frequent and severe among those <55 years (Table).The most frequent postvaccination symptom was injection site pain (39%).Common systemic symptoms included fatigue/malaise (34%),headache (23%),and muscle, bone or joint symptoms (13%).These were all less frequent after D3 than after D2 (Figure).Gastrointestinal symptoms were reported by 8.8%, which was slightly more frequent than after D2 (7.8%).Among those with postvaccination symptoms, the proportion with severe symptoms after D3 was lower than D2 for fatigue/ malaise, headache, dizziness and lightheadedness, fever/chills, and rheumatologic symptoms, but was slightly higher than D2 for gastrointestinal symptoms.Severe+ symptoms were seen in 17% after D2 and in 14% after D3. Of those with severe+ symptoms after D2, 34% had severe+ symptoms after D3.In contrast, about 22% had severe+ symptoms after D3 but did not report severe+ symptoms after D2.Conclusion:The frequency and severity of symptoms after a 3rd mRNA vaccine dose are generally similar or lower than those after a second dose.Furthermore, prior severe+ symptoms after D2 do not necessarily predict severe+ symptoms after D3. Further evaluation of postvaccination gastrointestinal symptoms in this population is warranted. (Figure Presented) (Table Presented)
ABSTRACT
Background: Vaccine-induced protection against SARS-CoV-2 infection is predominantly mediated by humoral immunity;protection against disease progression is primarily determined by cellular immunity. Patients with inflammatory bowel disease (IBD) have high rates of post-vaccination anti-Spike IgG [IgG(S)] seroconversion, but postvaccination immune responses relative to non-IBD controls have not been well described. We aimed to assess post-vaccination humoral (antibody) and cellular (T-cell) responses in IBD relative to healthcare worker (HCW) controls. Methods: We evaluated IBD patients enrolled in a US registry referred from 26 centers at 2, 8, and 16 weeks after completing 2 doses of SARSCoV- 2 mRNA vaccination and compared results to non-IBD non-immunosuppressed HCW participating in a parallel study. We analyzed plasma antibodies to the receptor binding domain of the viral spike protein using the SARS-CoV-2 IgG-II assay (Abbott Labs, Abbott Park, IL);IgG(S) > 50 AU/mL was defined as positive. Those with prior COVID were excluded. We also performed T-cell clonal analysis by T-cell receptor (TCR) immunosequencing at 8 weeks (Adaptive Biotechnologies, Seattle, WA). The breadth (number of unique sequences to a given protein) and depth (relative abundance of all the unique sequences to a given protein) of the T-cell clonal response were quantified using reference datasets. Analyses were adjusted for age, sex and vaccine type. Results: Overall, 1805 subjects were included (IBD n=1074 (65% Crohn's disease, 35% ulcerative colitis);HCW n=731). Age and sex were similar between both cohorts;Hispanic ethnicity and Asian race were less common among IBD than HCW (Table). Vaccine type included BNT162b2 (Pfizer) (75% of IBD, 98% of HCW) and the remainder mRNA-1274 (Moderna). IBD treatments included anti- TNF (46%), other biologics (33%), other immune suppressing therapy (9%), and no immune suppression (12%). Postvaccination antibody levels were lower among IBD than HCW both before and after adjusting for vaccine type (p<0.0001 each timepoint;Figure). After further restricting the IBD cohort to those on no immune-suppressive therapies, antibodies remained lower in IBD vs HCW at 2w (p=0.008) and 8w (p<0.0001), but not 16w (p=0.07). Among 321 subjects with available whole cell samples at 8 weeks (IBD n=163, HCW =158), Spikespecific TCR responses were similar between IBD and HCW for both clonal breadth and depth in both unadjusted and adjusted analyses;sub-analyses of those on biologics yielded similar results. Conclusion: Patients with IBD have dampened humoral responses, but similar cellular responses, after SARS-CoV-2 mRNA vaccination relative to HCW. These findings suggest a potentially greater risk of infection, but not of disease progression, among those with IBD, and should be considered to help guide booster dosing strategies for the IBD population. (Figure Presented) (Figure Presented) Figure: Post-vaccination immune responses: (A) Antibody responses are lower in IBD relative to non-IBD healthcare workers at 2, 8, and 16 weeks (p<0.0001 at each timepoint). In contrast, post-vaccination Spike-specific T-cell receptor clonal breadth (B1) and clonal depth (B2) at 8 weeks are similar in IBD compared to healthcare workers.
ABSTRACT
Organoids are emerging to be an excellent tool for studying human development and disease. The COVID-19 pandemic has highlighted the importance of physiologically relevant alveolar infection models that include both alveolar epithelial type 1 (AT1) and type 2 (AT2) cells. To address the need for an alveolar organoid culture system for respiratory research, we developed the PneumaCult™ Alveolar Organoid Expansion and Differentiation Media for the highly efficient expansion of isolated primary human AT2 cells and subsequent differentiation into AT1 cells. Alveolar organoids were established from a panel of various donors (n=5) by culturing purified human AT2 cells in Corning® Matrigel® domes with serum-free PneumaCult™ Alveolar Organoid Expansion Medium. Typically by day 10-14 the organoids are fully established and display a spherical morphology. Alveolar organoids can then be either expanded long-term by passaging cultures as single cells in Expansion Medium or differentiated into AT1 cells using the PneumaCult™ Alveolar Organoid Differentiation Medium. Organoids in PneumaCult™ Alveolar Organoid Expansion Medium contain self-renewing AT2 cells marked by the expression of HT2-280 in 89.9 +/- 14.5 (mean +/- SD;n=5 donors) of cells and the presence of Pro-SPC, demonstrate a great expansion potential of > 10,000-fold with more than 13 population doublings within 10 passages (n=5 donors). Alveolar organoids differentiated for 10 days in the PneumaCult™ Alveolar Organoid Differentiation Medium downregulate AT2 markers HT2-280 and Pro-SPC and start expressing AT1 markers HT1-56 in 93.8 +/- 7.2 (mean +/- SD;n=5 donors) of cells and are positive for RAGE and GPRC5a. Furthermore, we assessed the expression of SARS-CoV-2 entry receptor ACE2, which is present in both undifferentiated and differentiated alveolar organoids.To investigate the use of these alveolar organoids for infectious disease modeling, AT2-containing alveolar organoids were transduced with a GFP-labelled Respiratory Syncytial Virus (RSV). Alveolar organoids were susceptible to viral infection and replication was confirmed by fluorescence microscopy and quantitative PCR. In summary, the PneumaCult™ Alveolar Organoid Expansion and Differentiation Media are highly efficient and reproducible tools for the feeder-free expansion of AT2 cells and robust differentiation into AT1 cells, which can be used for infectious disease modeling.
ABSTRACT
Objective To explore the application and safety of apheresis technology in collection of Coronavirus Disease 2019 (COVID-19) convalescent plasma (CP), and to analyze the quality characteristics of the plasma. Methods The general data of COVID-19 convalescent plasma (CP) donors, including gender, age, date of discharge or release from medical isolation, were collected based on informed consent. After physical examination, the CP was collected by apheresis technology with plasma separator, inactivated with methylene blue, and determined for severe acute respiratory symptom Coronavirus 2 (SARS-CoV-2) nucleic acid and specific antibody (RBD-IgG) against SARS-CoV-2. Results The collection process went well, and no serious adverse events related to plasma collection were reported during or after the collection. The average age of COVID-19 CP donors was 38 years (n = 933). The distributions of blood groups A, B, AB and 0 in RhD (+) COVID-19 CP were 33. 4%, 29. 2%, 10% and 27. 2% respectively. The plasma donation date was 18 d from the discharge date in average. All the test results of SARS-CoV-2 nucleic acid in CP were negative, while the proportion of plasma samples at SARS-CoV-2 antibody titer of more than 1: 160 was 92. 60%. Conclusion Apheresis technology was safe and reliable. The COVID-19 CP contained high titer antibody. Large-scale collection and preparation of inactivated plasma against SARS-CoV-2 played an important role in the treatment of COVID-19.
ABSTRACT
The increasing availability of behavioral data about consumers offers great promise for understanding their shifting preferences over time. This poses an important challenge for business practitioners - particularly entrepreneurs and investors - who wish to be the first to identify and satisfy consumers' unmet needs. Here, we introduce the Consumer Deviation Index (CDI) as a means of generating forecasts from historical time series data in order to isolate emerging behaviors that fall outside the realm of expectation. These deviations serve as leading indicators of market opportunities to fulfill pockets of "latent demand"before they fully manifest across a consumer population. We illustrate the application of this methodology to behavior change during the height of COVID-19 stay-at-home restrictions, and to the initial reopening of the U.S. economy post-pandemic. We discuss implications for optimizing product development and innovation to better serve consumers' ever-changing needs. © 2022 ACM.
ABSTRACT
Deep learning methods have been extensively investigated for rapid and precise computer-aided diagnosis during the outbreak of the COVID-19 epidemic. However, there are still remaining issues to be addressed, such as distinguishing COVID-19 in the complex scenario of multi-type pneumonia classification. In this paper, we aim to boost the COVID-19 diagnostic performance with more discriminative deep representations of COVID and non-COVID categories. We propose a novel COVID-19 diagnosis approach with contrastive representation learning to effectively capture the intra-class similarity and inter-class difference. Besides, we design an adaptive joint training strategy to integrate the classification loss, mixup loss, and contrastive loss. Through the joint loss function, we obtain the high-level representations which are highly discriminative in COVID-19 screening. Extensive experiments on two chest CT image datasets, i.e., CC-CCII dataset and COV19-CT-DB database, demonstrate the effectiveness of our proposed approach in COVID-19 diagnosis. Our method won the first prize in the ICCV 2021 Covid-19 Diagnosis Competition of AI-enabled Medical Image Analysis Workshop. Our code is publicly available at https://github.com/houjunlin/Team-FDVTS-COVID-Solution.